The following are some of the more common tests performed during pregnancy:
First trimester screening is a combination of fetal ultrasound and maternal blood testing performed during the first trimester of pregnancy. This screening process can help to determine the risk of the fetus having certain birth defects. Screening tests may be used alone or in combination with other tests.
There are three parts of first trimester screening:
Ultrasound test for fetal nuchal translucency (NT). Nuchal translucency screening uses an ultrasound test to examine the area at the back of the fetal neck for increased fluid or thickening.
Two maternal serum (blood) tests. The blood tests measure two substances found in the blood of all pregnant women:
Pregnancy-associated plasma protein screening (PAPP-A)--a protein produced by the placenta in early pregnancy. Abnormal levels are associated with an increased risk for chromosome abnormality.
Human chorionic gonadotropin (hCG)--a hormone produced by the placenta in early pregnancy. Abnormal levels are associated with an increased risk for chromosome abnormality.
When used together as first trimester screening tests, nuchal translucency screening and maternal blood tests have a greater ability to determine if the fetus might have a birth defect, such as Down syndrome (trisomy 21) and trisomy 18.
If the results of these first trimester screening tests are abnormal, genetic counseling is recommended. Additional testing such as chorionic villus sampling, amniocentesis, cell-free fetal DNA, or other ultrasounds may be needed for accurate diagnosis.
Second trimester prenatal screening may include several blood tests, called multiple markers. These markers provide information about a woman's risk of having a baby with certain genetic conditions or birth defects. Screening is usually performed by taking a sample of the mother's blood between the 15th and 20th weeks of pregnancy (16th to 18th is ideal). The multiple markers include:
Alpha-fetoprotein screening (AFP). This blood test measures the level of alpha-fetoprotein in the mothers' blood during pregnancy. AFP is a protein normally produced by the fetal liver and is present in the fluid surrounding the fetus (amniotic fluid), and crosses the placenta into the mother's blood. The AFP blood test is also called MSAFP (maternal serum AFP).
Abnormal levels of AFP may signal the following:
Open neural tube defects (ONTD), such as spina bifida
Other chromosomal abnormalities
Defects in the abdominal wall of the fetus
Twins--more than one fetus is making the protein
A miscalculated due date, as the levels vary throughout pregnancy
hCG. This is human chorionic gonadotropin hormone (a hormone produced by the placenta)
Estriol. This is a hormone produced by the placenta
Inhibin. This is a hormone produced by the placenta
Abnormal test results of AFP and other markers may indicate the need for additional testing. Usually an ultrasound is performed to confirm the dates of the pregnancy and to look at the fetal spine and other body parts for defects. An amniocentesis may be needed for accurate diagnosis.
Multiple marker screening is not diagnostic. This means it is not 100 percent accurate, and is only a screening test to determine who in the population should be offered additional testing for their pregnancy. There can be false-positive results--indicating a problem when the fetus is actually healthy or false negative results--indicating a normal result when the fetus actually does have a health problem.
When a woman has both first and second trimester screening tests performed, the ability of the tests to detect an abnormality is greater than using just one screening independently. Nearly all cases of Down Syndrome can be detected when both first and second trimester screening are used.
An amniocentesis is a procedure used to obtain a small sample of the amniotic fluid that surrounds the fetus to diagnose chromosomal disorders and open neural tube defects (ONTDs), such as spina bifida. Testing is available for other genetic defects and disorders depending on the family history and availability of laboratory testing at the time of the procedure. An amniocentesis is generally offered to women between the 15th and 20th weeks of pregnancy who are at increased risk for chromosome abnormalities, such as women who are over age 35 years of age at delivery, or those who have had an abnormal maternal serum screening test, indicating an increased risk for a chromosomal abnormality or neural tube defect.
An amniocentesis is a procedure that involves inserting a long, thin needle through the mother's abdomen into the amniotic sac to withdraw a small sample of the amniotic fluid for examination. The amniotic fluid contains cells shed by the fetus, which contain genetic information. Although specific details of each procedure vary slightly, generally, an amniocentesis follows this process:
The woman's abdomen is cleansed with an antiseptic.
The doctor may or may not give a local anesthetic to numb the skin.
Ultrasound is used to help guide a hollow needle into the amniotic sac.
A small sample of fluid is withdrawn for laboratory analysis.
Strenuous activities should be avoided for 24 hours following an amniocentesis.
Women may feel some cramping during or after the amniocentesis.
Women with twins or other multiples need sampling from each amniotic sac, in order to study each baby. Depending on the position of the baby, placenta, amount of fluid, or patient's anatomy, sometimes the amniocentesis cannot be performed. The fluid is sent to a genetics laboratory so that the cells can grow and be analyzed. Alpha-fetoprotein, a protein made by the fetus that is present in the fluid, is also measured to rule out an open neural tube defect, such as spina bifida. Results are usually available in about 10 days to two weeks, depending on the laboratory.
Chorionic villus sampling (CVS) is a prenatal test that involves taking a sample of some of the placental tissue. This tissue contains the same genetic material as the fetus and can be tested for chromosomal abnormalities and some other genetic problems. Testing is available for other genetic defects and disorders depending on the family history and availability of laboratory testing at the time of the procedure. In comparison to amniocentesis (another type of prenatal test), CVS does not provide information on neural tube defects such as spina bifida. For this reason, women who undergo CVS also need a follow-up blood test between 16 to 18 weeks of their pregnancy, to screen for neural tube defects.
CVS may be offered to women who are at increased risk for chromosomal abnormalities or have a family history of a genetic defect that is testable from the placental tissue. CVS is usually performed between the 10th and 12th weeks of pregnancy. Although exact methods can vary, the procedure involves inserting a small tube called a catheter through a woman's vagina and into her cervix and usually follows this process:
Ultrasound is used to guide the catheter into place near the placenta.
Tissue is removed using a syringe on the other end of the catheter.
Another method is transabdominal CVS, which involves inserting a needle through the woman's abdomen and into her uterus to sample the placental cells.
Women may feel some cramping during and after the CVS procedure.
The tissue samples are sent to a genetic laboratory to grow and be analyzed. Results are usually available in about 10 days to two weeks, depending on the laboratory.
Women with twins or other multiples usually need sampling from each placenta. However, because of the complexity of the procedure, and positioning of the placentas, CVS is not always feasible or successful with multiples.
Some women may not be candidates for CVS or may not obtain results that are 100 percent accurate, and may therefore require a follow-up amniocentesis. In some cases there is an active vaginal infection, such as herpes or gonorrhea, which will prohibit the procedure. Other times the doctor obtains a sample that does not have enough tissue to grow in the laboratory, such that results are incomplete or inconclusive.
During late pregnancy and during labor, your doctor may want to monitor the fetal heart rate and other functions. Fetal heart rate monitoring is a method of checking the rate and rhythm of the fetal heartbeat. The average fetal heart rate is between 110 and 160 beats per minute. The fetal heart rate may change as the fetus responds to conditions in the uterus. An abnormal fetal heart rate or pattern may mean that the fetus is not getting enough oxygen or there are other problems. An abnormal pattern also may mean that an emergency or cesarean delivery is needed.
Using a fetoscope (a type of stethoscope) to listen to the fetal heart beat is the most basic type of fetal heart rate monitoring. Another type of monitoring is with a hand held Doppler device. This is often used during prenatal visits to count the fetal heart rate. During labor, continuous electronic fetal monitoring is often used. Although the specific details of each procedure vary slightly, generally, electronic fetal monitoring follows this process:
Gel is applied to the mother's abdomen to act as a medium for the ultrasound transducer.
The ultrasound transducer is attached to the abdomen with straps and transmits the fetal heartbeat to a recorder. The fetal heart rate is displayed on a screen and printed onto special paper.
During contractions, an external tocodynamometer (a monitoring device that is placed over the top of the uterus with a belt) can record the patterns of contractions.
Sometimes, internal fetal monitoring is necessary for a more accurate reading of the fetal heart rate. Your bag of waters (amniotic fluid) must be broken and your cervix must be partially dilated to use internal monitoring. Internal fetal monitoring involves inserting an electrode through the dilated cervix and attaching the electrode to the scalp of the fetus, called a fetal scalp electrode.
The initial 1-hour test is a glucose challenge test. If the results are abnormal, a glucose tolerance test is done.
A glucose tolerance test, usually conducted in the 24 to 28 weeks of pregnancy, measures levels of sugar (glucose) in the mother's blood. Abnormal glucose levels may indicate gestational diabetes.
The glucose tolerance test is done if the woman has an elevated 1-hour glucose challenge test.
Although the specific details of each procedure vary slightly, generally, a glucose tolerance test follows this process:
The mother-to-be may be asked to only drink water on the day the glucose tolerance test is given.
An initial fasting sample of blood is drawn from a vein.
You will be given a special glucose solution to drink.
Blood will be drawn several times over the course of several hours to measure the glucose levels in your body.
Group B Streptococcus (GBS) are bacteria found in the lower genital tract of about 25 percent of all women. GBS infection usually causes no problems in women before pregnancy, but can cause serious illness in the mother during pregnancy. GBS may cause chorioamnionitis (a severe infection of the placental tissues) and postpartum infection. Urinary tract infections caused by GBS can lead to preterm labor and birth, or pyelonephritis and sepsis.
GBS is the most common cause of life-threatening infections in newborns, including pneumonia and meningitis. Newborn babies contract the infection during pregnancy or from the mother's genital tract during labor and delivery.
The Centers for Disease Control and Prevention recommends screening of all pregnant women for vaginal and rectal group B strep colonization between 35 to 37 weeks' gestation. Treatment of mothers with certain risk factors or positive cultures is important to reduce the risk of transmission of GBS to the baby. Babies whose mothers receive antibiotic treatment for a positive GBS test are 20 times less likely to develop the disease than those without treatment.
An ultrasound scan is a diagnostic technique which uses high-frequency sound
waves to create an image of the internal organs. A screening ultrasound is sometimes done during the course of a pregnancy to check normal fetal growth and verify the due date. Ultrasounds may be performed at various times throughout pregnancy for different reasons:
In the first trimester
To establish the dates of a pregnancy
To determine the number of fetuses and identify placental structures
To diagnose an ectopic pregnancy or miscarriage
To examine the uterus and other pelvic anatomy
In some cases to detect fetal abnormalities
Mid-trimester (sometimes called the 18 to 20 week scan)
To confirm pregnancy dates
To determine the number of fetuses and examine the placental structures
To assist in prenatal tests, such as an amniocentesis
To examine the fetal anatomy for presence of abnormalities
To check the amount of amniotic fluid
To examine blood flow patterns
To observe fetal behavior and activity
To examine the placenta
To measure the length of the cervix
To monitor fetal growth
To monitor fetal growth
To check the amount of amniotic fluid
As part of the biophysical profile
To determine the position of a fetus
To assess the placenta
Although the specific details of each procedure vary slightly, generally, ultrasounds follow this process. Two types of ultrasounds can be performed during pregnancy:
In an abdominal ultrasound, gel is applied to the abdomen and the ultrasound transducer glides over the gel on the abdomen to create the image.
In a transvaginal ultrasound, a smaller ultrasound transducer is inserted into the vagina and rests against the back of the vagina to create an image. A transvaginal ultrasound produces a sharper image and is often used in early pregnancy.
There are several types of ultrasound imaging techniques. The most common is two dimensional, or 2D. This gives a flat picture of one aspect of the image.
If more information is needed, a 3D ultrasound examination can be performed. This technique, which provides a three-dimensional picture, requires a special machine and special training. But the 3D image allows the health care provider to see width, height, and depth of images, which can be helpful in diagnosis. The 3D images can also be captured and saved for later review.
The latest technology is 4D ultrasound, which allows the health care provider to visualize the unborn baby moving in real-time. With 4D imaging, a three-dimensional image is continuously updated, providing a "live action" view. These images often have a golden color, which helps show shadows and highlights.
Ultrasound images may be captured in still photographs or on video to document findings.
Ultrasound is a technique that is constantly being improved and refined. As with any test, results may not be completely accurate. However, ultrasound can provide valuable information for parents and health care providers to help manage and care for the pregnancy and fetus. In addition, ultrasound gives parents a unique opportunity to see their baby before birth, helping them to bond and establish an early relationship.
Fetal ultrasound has no known risks other than mild discomfort due to pressure from the transducer on the abdomen or in the vagina. No radiation is used during the procedure.
Transvaginal ultrasound requires covering the ultrasound transducer in a plastic/latex sheath, which may cause a reaction in patients with a latex allergy.
Fetal ultrasound is sometimes offered in nonmedical settings to provide keepsake images or videos for parents. While the ultrasound procedure itself is considered safe, it is possible that untrained personnel may give parents false assurances about their baby's well-being, or perhaps an abnormality may be missed. Having ultrasound performed by trained medical personnel who can correctly interpret findings is recommended. Talk with your doctor or midwife if you have questions.
Many genetic abnormalities can be diagnosed before birth. Your doctor or midwife may recommend genetic testing during the pregnancy if you or your partner have a family history of genetic disorders and/or you have had a fetus or baby with a genetic abnormality.
Examples of genetic disorders that can be diagnosed before birth include the following:
Duchenne muscular dystrophy
Sickle cell anemia
Polycystic kidney disease
Genetic screening methods may include the following:
Alpha-fetoprotein test (AFP) or multiple marker test
Chorionic villus sampling (CVS)
Percutaneous umbilical blood sampling (withdrawing a small sample of the fetal blood from the umbilical cord)